Literature DB >> 23866818

Economic assessment of Q fever in the Netherlands.

M A P M van Asseldonk1, J Prins, R H M Bergevoet.   

Abstract

In this paper the economic impact of controlling the Q fever epidemic in 2007-2011 in the Netherlands is assessed. Whereas most of the long-term benefits of the implemented control programme stem from reduced disease burden and human health costs, the majority of short-term intervention costs were incurred in the dairy goat sector. The total intervention cost in agriculture amounted approximately 35,000 Euro per DALY occurred. By culling of infected animals, breeding prohibition and vaccination, the epidemic seems to be under control. As the dairy goat vaccination programme continues, future expenses in maintaining the current protected status are relatively low.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  DALY; Goat; Q-fever; Utility

Mesh:

Year:  2013        PMID: 23866818     DOI: 10.1016/j.prevetmed.2013.06.002

Source DB:  PubMed          Journal:  Prev Vet Med        ISSN: 0167-5877            Impact factor:   2.670


  24 in total

Review 1.  Right on Q: genetics begin to unravel Coxiella burnetii host cell interactions.

Authors:  Charles L Larson; Eric Martinez; Paul A Beare; Brendan Jeffrey; Robert A Heinzen; Matteo Bonazzi
Journal:  Future Microbiol       Date:  2016-07-15       Impact factor: 3.165

2.  De novo NAD synthesis is required for intracellular replication of Coxiella burnetii, the causative agent of the neglected zoonotic disease Q fever.

Authors:  Mebratu A Bitew; Chen Ai Khoo; Nitika Neha; David P De Souza; Dedreia Tull; Nadeeka K Wawegama; Hayley J Newton; Fiona M Sansom
Journal:  J Biol Chem       Date:  2018-10-12       Impact factor: 5.157

3.  First serologic survey of Q fever in free-range yaks in China.

Authors:  M Y Yin; Q D Tan; S Y Qin; L Y Hu; G H Liu; D H Zhou; X Q Zhu
Journal:  Iran J Vet Res       Date:  2015       Impact factor: 1.376

4.  Seroprevalence of Coxiella burnetii Antibodies Among Ruminants and Occupationally Exposed People in Thailand, 2012-2013.

Authors:  Pawinee Doung-Ngern; Teerasak Chuxnum; Decha Pangjai; Pattarin Opaschaitat; Nattinee Kittiwan; Pranee Rodtian; Noppawan Buameetoop; Gilbert J Kersh; Pawin Padungtod
Journal:  Am J Trop Med Hyg       Date:  2017-01-23       Impact factor: 2.345

5.  To die or not to die: Programmed cell death responses and their interactions with Coxiella burnetii infection.

Authors:  Chelsea A Osbron; Alan G Goodman
Journal:  Mol Microbiol       Date:  2022-02-02       Impact factor: 3.979

6.  Improved correlation of human Q fever incidence to modelled C. burnetii concentrations by means of an atmospheric dispersion model.

Authors:  Jeroen P G van Leuken; Jan van de Kassteele; Ferd J Sauter; Wim van der Hoek; Dick Heederik; Arie H Havelaar; Arno N Swart
Journal:  Int J Health Geogr       Date:  2015-04-01       Impact factor: 3.918

Review 7.  Fatigue following Acute Q-Fever: A Systematic Literature Review.

Authors:  Gabriella Morroy; Stephan P Keijmel; Corine E Delsing; Gijs Bleijenberg; Miranda Langendam; Aura Timen; Chantal P Bleeker-Rovers
Journal:  PLoS One       Date:  2016-05-25       Impact factor: 3.240

8.  Rapid Assessment of Stakeholder Concerns about Public Health. An Introduction to a Fast and Inexpensive Approach Applied on Health Concerns about Intensive Animal Production Systems.

Authors:  Marleen Kraaij-Dirkzwager; Joost van der Ree; Erik Lebret
Journal:  Int J Environ Res Public Health       Date:  2017-12-11       Impact factor: 3.390

9.  Characterisation of putative lactate synthetic pathways of Coxiella burnetii.

Authors:  Janine Hofmann; Mebratu A Bitew; Miku Kuba; David P De Souza; Hayley J Newton; Fiona M Sansom
Journal:  PLoS One       Date:  2021-08-13       Impact factor: 3.240

10.  Detection of Coxiella burnetii in Ambient Air after a Large Q Fever Outbreak.

Authors:  Myrna M T de Rooij; Floor Borlée; Lidwien A M Smit; Arnout de Bruin; Ingmar Janse; Dick J J Heederik; Inge M Wouters
Journal:  PLoS One       Date:  2016-03-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.